You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on HER2 biomarkers.
HER2-targeted bispecific antibody ZW25 will be used in combination with other drugs for HER2-positive breast cancer and gastroesophageal adenocarcinoma.
The company is testing out its immune-stimulating antibody conjugate platform technology, hitching its proprietary molecule to trastuzumab.
A drug supply agreement with Pfizer will enable Jiangsu Alphamab to study the combination of its dual-HER2 signal blocking drug, KNO26, and Ibrance.
The approval limits the drug's use to patients who are refractory or intolerant to standard-of-care treatments and contains warnings about the risk of interstitial lung disease.
The precision oncology startup is gearing up to enroll patients in its tissue-agnostic Phase I/II trial for its investigational new drug BDTX-189.
The FDA had previously approved neratinib as an extended adjuvant therapy for patients with early-stage HER2-overexpressed or amplified breast cancer, following adjuvant treatment with trastuzumab.
The study showed that patients with targetable genomic markers, especially HER2 alterations, responded well to chemotherapy-free treatments.
The NDA, based on data from a randomized Phase II trial, is for the use of tucatinib combined with trastuzumab and capecitabine for HER2-positive breast cancer patients.
The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.
A roundup of some of the precision oncology-focused research presented at the Gastrointestinal Cancer Symposium in San Francisco, Jan. 23 to 25.